For more nearly 20 years Juergen is involved in projects concentrating on CDx.
CDx is one of the most challenging chances in pharmaceutical business and especially in biotechnological developed compounds. Having a perfect match between therapeutic and an IVD answering the question „Works: Yes / No“ or in EU „Major side effects to be expected: Yes/No“ makes all steps regarding reimbursement much easier and helps confirming the superiority vs. many other therapeutic approaches.
For Steinbeis Lifescience Consultancy CDx is one of the main challenges in preparing products for Market Approval and even more for Market Access. We are well prepared to support your work and your success.